
Serum Institute to manufacture TB vaccine M72/AS01E
The story in brief
The double-blind, randomised trial of the novel tuberculosis vaccine M72/AS01E, involving 20,000 participants across five countries, has completed enrolment. Gates MRI, with funding from the Gates Foundation and Wellcome, is sponsoring the Phase 3 trial. Serum Institute of India, selected for its proven track record, plans to invest over $100 million to strengthen manufacturing readiness and support global supply.